Baillie Gifford & Co. reduced its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 49.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,275,769 shares of the life sciences company's stock after selling 5,194,534 shares during the period. Baillie Gifford & Co. owned about 3.32% of Illumina worth $734,598,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ILMN. Annis Gardner Whiting Capital Advisors LLC purchased a new stake in shares of Illumina in the third quarter worth $30,000. State of Wyoming purchased a new stake in shares of Illumina in the second quarter worth $32,000. Quent Capital LLC increased its stake in shares of Illumina by 71.2% in the third quarter. Quent Capital LLC now owns 250 shares of the life sciences company's stock worth $34,000 after purchasing an additional 104 shares in the last quarter. VisionPoint Advisory Group LLC increased its stake in shares of Illumina by 344.6% in the third quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company's stock worth $34,000 after purchasing an additional 193 shares in the last quarter. Finally, ST Germain D J Co. Inc. purchased a new stake in shares of Illumina in the second quarter worth $36,000. 89.42% of the stock is owned by hedge funds and other institutional investors.
Illumina Trading Up 2.7 %
ILMN stock traded up $3.45 during trading on Tuesday, hitting $133.57. The company had a trading volume of 1,735,437 shares, compared to its average volume of 1,775,038. The firm has a market capitalization of $21.27 billion, a P/E ratio of -18.20 and a beta of 1.19. Illumina, Inc. has a 52-week low of $89.00 and a 52-week high of $232.88. The company has a 50 day simple moving average of $136.65 and a 200-day simple moving average of $128.47. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.26.
Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, February 8th. The life sciences company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.01 by $0.13. The company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The firm's revenue was up 3.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.14 EPS. As a group, research analysts forecast that Illumina, Inc. will post 0.91 earnings per share for the current fiscal year.
Insider Buying and Selling at Illumina
In other Illumina news, CEO Jacob Thaysen bought 7,330 shares of the business's stock in a transaction on Thursday, February 22nd. The shares were acquired at an average price of $135.29 per share, with a total value of $991,675.70. Following the transaction, the chief executive officer now owns 14,861 shares of the company's stock, valued at approximately $2,010,544.69. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.13% of the company's stock.
Wall Street Analyst Weigh In
ILMN has been the subject of a number of analyst reports. HSBC cut shares of Illumina from a "buy" rating to a "hold" rating in a research note on Tuesday, January 16th. Bank of America lowered shares of Illumina from a "neutral" rating to an "underperform" rating and dropped their target price for the stock from $140.00 to $100.00 in a research report on Tuesday, December 12th. Stephens restated an "overweight" rating and set a $170.00 target price on shares of Illumina in a research report on Wednesday, February 14th. StockNews.com upgraded shares of Illumina from a "hold" rating to a "buy" rating in a research report on Friday, February 16th. Finally, Wolfe Research began coverage on shares of Illumina in a research report on Wednesday, December 13th. They set an "outperform" rating and a $175.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, Illumina currently has an average rating of "Hold" and a consensus target price of $166.70.
Get Our Latest Stock Report on Illumina
About Illumina
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Further Reading
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
